Drugs in R & D

, Volume 2, Issue 6, pp 361–374 | Cite as

Advances in the Pharmacotherapy of Migraine

How Knowledge of Pathophysiology is Guiding Drug Development
Section 1: Migraine Leading Article

Abstract

The pharmacotherapy of migraine has advanced in parallel with our understanding of the pathophysiology of the disease. It is likely that it is the gap in our knowledge of the pathogenesis as opposed to the pathophysiology of migraine which hinders development of preventative agents. This century has seen the shift from the vascular theory of migraine pathophysiology (i.e. that cranial vessels were the prime movers in the disorder and thus vasoconstriction would be the prime treatment) to a more integrated neurovascular theory. The neurovascular theory takes the view that vascular change is secondary to neural activation, so changes such as release of trigeminal neuropeptides is predicted, has been demonstrated and suggests a possible new treatment. Similarly, it may be possible to block trigeminal nociceptive transmission in the trigeminal nucleus which might avoid the vascular adverse effects that, while small, plague current treatments. The future for migraine and cluster headache, the neurovascular headaches, is bright as we unravel their biology and this leads to further therapeutic advances.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wolff HG. Headache and other head pain. New York: Oxford University Press, 1963Google Scholar
  2. 2.
    Goadsby PJ. Animal models of migraine: which model, why and for what? In: Edvinsson L, editor. Migraine and headache pathophysiology. London: Martin Dunitz, 1999: 155–69Google Scholar
  3. 3.
    Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Ann Rev Med 1993; 44: 145–54PubMedGoogle Scholar
  4. 4.
    Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183–7PubMedGoogle Scholar
  5. 5.
    Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 1991; 31: 365–71PubMedGoogle Scholar
  6. 6.
    Goadsby PJ. How do the currently used prophylactic agents work in migraine? Cephalalgia 1997; 17: 85–92PubMedGoogle Scholar
  7. 7.
    Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1: 658–60PubMedGoogle Scholar
  8. 8.
    May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiological implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metabol 1999; 19: 115–27Google Scholar
  9. 9.
    Davies GM, Santanello NC, Kramer M, et al. Determinants of patient satisfaction with migraine treatment [abstract]. Headache 1998; 38: 380Google Scholar
  10. 10.
    Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States: relation to age, income, race and other sociodemographic factors. JAMA 1992; 267: 64–9PubMedGoogle Scholar
  11. 11.
    Ray BS, Wolff HG. Experimental studies on headache: pain sensitive structures of the head and their significance in headache. Arch Surg 1940; 41: 813–56Google Scholar
  12. 12.
    Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938; 39: 737–63Google Scholar
  13. 13.
    Feniuk W, Humphrey PPA, Perren MJ, et al. Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J Neurol 1991; 238: S57–61PubMedGoogle Scholar
  14. 14.
    Johnston BM, Saxena PR. The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol 1978; 63: 541–9PubMedGoogle Scholar
  15. 15.
    Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. In pressGoogle Scholar
  16. 16.
    Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache: increase in hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy 1961; 19: 55–8Google Scholar
  17. 17.
    Curran DA, Hinterberger H, Lance JW. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 1965; 88: 997–1010PubMedGoogle Scholar
  18. 18.
    Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol 1967; 16: 544–52PubMedGoogle Scholar
  19. 19.
    Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology (Minneap.) 1960; 10: 107–11Google Scholar
  20. 20.
    Lance JW, Anthony M, Hinterberger H. The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 1967; 7: 93–102PubMedGoogle Scholar
  21. 21.
    Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46: 157–203PubMedGoogle Scholar
  22. 22.
    Jasper JR, Kosaka A, To ZP, et al. Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7(b)). Br J Pharmacol 1997; 122: 126–32PubMedGoogle Scholar
  23. 23.
    Hartig PR, Hoyer D, Humphrey PPA, et al. Alignment of receptor nomenclature with the human genome: classification of 5HT-1B and 5-HT1D receptor subtypes. Trends Pharmacol Sci 1996; 17: 103–5PubMedGoogle Scholar
  24. 24.
    Phebus LA, Johnson KW, Zgombick JM, et al. Characterization of LY334370 as a pharmacological tool to study 5HT1F receptors-binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 1997; 61: 2117–26PubMedGoogle Scholar
  25. 25.
    John GW, Pauwels PJ, Perez M, et al. F11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. J Pharmacol Exp Ther 1999; 290: 83–95PubMedGoogle Scholar
  26. 26.
    Humphrey PPA, Feniuk W, Perren MJ, et al. Serotonin and migraine. Ann N Y Acad Sci 1990; 600: 587–98PubMedGoogle Scholar
  27. 27.
    Goadsby PJ. 5-HT1B/1D agonists in migraine: comparative pharmacology and its therapeutic implications. CNS Drugs 1998; 10: 271–86Google Scholar
  28. 28.
    Humphrey PPA, Feniuk W, Marriott AS, et al. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 1991; 31: 282–90PubMedGoogle Scholar
  29. 29.
    Hoskin KL, Classey JD, Goadsby PJ. 5HT 1B receptors in intracranial extracerebral vascular structures of the cat [abstract]. Cephalalgia 1999; 19: 402Google Scholar
  30. 30.
    Bax WA, Heuven-Nolsen DV, Simoons ML, et al. 5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement of 5-HT2 and 5-HT1D-like receptors, and a comparison with grafted veins. Naunyn-Schmiedeberg’s Arch Pharmacol 1992; 345: 500–8Google Scholar
  31. 31.
    Longmore J, Shaw D, Smith D, et al. Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997; 17: 833–42PubMedGoogle Scholar
  32. 32.
    Spira PJ, Mylecharane EJ, Misbach J, et al. Internal and external carotid vascular responses to vasoactive agents in the monkey. Neurology 1978; 28: 162–73PubMedGoogle Scholar
  33. 33.
    Perren MJ, Feniuk W, Humphrey PPA. Vascular 5-HT1-like receptors that mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetised dogs are not of the 5-HT1A or 5-HT1D subtype. Br J Pharmacol 1991; 102: 191–7PubMedGoogle Scholar
  34. 34.
    Friberg L, Olesen J, Iversen HK, et al. Migraine pain associated with middle cerebral artery dilatation-reversal by sumatriptan. Lancet 1991; 338: 13–7PubMedGoogle Scholar
  35. 35.
    Connor HE, Stubbs CM, Feniuk W, et al. Effect of sumatriptan, a selective 5-HT1-like receptor agonist, on pial vessel diameter in anaesthetised cats. J Cereb Blood Flow Metab 1992; 12: 514–9PubMedGoogle Scholar
  36. 36.
    Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in man and cat. Ann Neurol 1993; 33: 48–56PubMedGoogle Scholar
  37. 37.
    Saxena PR. 5-HT in migraine: an introduction. J Neurol 1991; 238: S36–7PubMedGoogle Scholar
  38. 38.
    Villalon CM, Bom AH, Boer MOD, et al. Effects of S9977 and dihydroergotamine in an animal experimental model for migraine. Pharmacol Res 1992; 25: 125–37PubMedGoogle Scholar
  39. 39.
    De Vries P, Apaydin S, Villalon CM, et al. Interactions of GR127935, a 5-HT(1B/D) receptor ligand, with functional 5-HT receptors. Naunyn Schmiedebergs Arch Pharmacol 1997; 355 (4): 423–30PubMedGoogle Scholar
  40. 40.
    Den Boer MO, Villalon CM, Saxena PR. 5-HT1-like receptors mediate changes in porcine carotid hemodynamics: are 5-HT1D receptors involved? Naunyn-Schmiedeberg’s Arch Pharmacol 1992; 345: 509–15Google Scholar
  41. 41.
    Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J Neurosci 1987; 7: 4129–36PubMedGoogle Scholar
  42. 42.
    Dimitriadou V, Buzzi MG, Theoharides TC, et al. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992; 48: 187–203PubMedGoogle Scholar
  43. 43.
    Headache Classification Committee of The International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1–96Google Scholar
  44. 44.
    Drummond PD. Scalp tenderness and sensitivity to pain in migraine and tension headache. Headache 1987; 27: 45–50PubMedGoogle Scholar
  45. 45.
    Burstein R, Goor-Aryeh I, Yarnitsky D, et al. Cutaneous allodynia during migraine: a new neurological finding and a new insight into the pathophysiology. 9thWorld Congress on Pain; 1999 Aug 22–27; Vienna. Vienna: IASP Press, 1999: 419Google Scholar
  46. 46.
    Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989; 165: 251–8PubMedGoogle Scholar
  47. 47.
    Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202–6PubMedGoogle Scholar
  48. 48.
    Yu X-J, Waeber C, Castanon N, et al. 5-carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl-tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors. Mol Pharmacol 1996; 49: 761–5PubMedGoogle Scholar
  49. 49.
    Bou J, Domenech T, Gras J, et al. Pharmacological profile of almotriptan, a novel antimigraine agent. Cephalalgia 1997; 17: 421–2Google Scholar
  50. 50.
    Gupta P, Brown D, Butler P, et al. Preclinical in vivo pharmacology of eletriptan (UK 116,044): a potent and selective partial agonist at the 5HT1D-like receptor [abstract]. Cephalalgia 1996; 16: 386Google Scholar
  51. 51.
    Connor HE, Feniuk W, Beattie DT, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997; 17: 145–52PubMedGoogle Scholar
  52. 52.
    Williamson DJ, Shepheard SL, Hill RG, et al. The novel antimigraine agent rizatriptan inhibits neurogenic dural vasodilatation and extravasation. Eur. J Pharmacol 1997; 328: 61–4PubMedGoogle Scholar
  53. 53.
    Martin GR, Robertson AD, MacLennan SJ, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 1997; 121: 157–64PubMedGoogle Scholar
  54. 54.
    Yocca FD, Gylys JA, Smith DW, et al. BMS-181885: a clinically effective migraine abortive with peripherovascular and neuronal 5HT1D antagonist properties [abstract]. Cephalalgia 1997; 17: 404Google Scholar
  55. 55.
    Couch JR, Saper J, Meloche JP. Treatment of migraine with BMS180048: response at 2 hours. Headache 1996; 36: 523–30PubMedGoogle Scholar
  56. 56.
    Ryan RE, Elkind A, Goldstein J. Twenty-four hour effectiveness of BMS 180048 in the acute treatment of migraine headaches. Headache 1997; 37: 245–8PubMedGoogle Scholar
  57. 57.
    Lee WK, Limmroth V, Ayata C, et al. Peripheral GABA-A receptor mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 1995; 116: 1661–7PubMedGoogle Scholar
  58. 58.
    Maassen Van DenBrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98: 25–30Google Scholar
  59. 59.
    Lee WS, Moskowitz MA. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638, exhibit enhanced potency against neurogenic inflammation in duramater. Brain Res 1993; 626: 303–5PubMedGoogle Scholar
  60. 60.
    Gupta P, Brown D, Butler P, et al. The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP122,288, a selective inhibitor of neurogenic inflammation. Br J Pharmacol 1995; 116: 2385–90PubMedGoogle Scholar
  61. 61.
    Roon K, Diener HC, Ellis P, et al. CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical studies. Cephalalgia 1997; 17: 245Google Scholar
  62. 62.
    Giles H, Honey A, Edvinsson L, et al. Pre-clinical pharmacology of 4991W93, a potent inhibtor of neurogenic plasma protein extravasation [abstract]. Cephalalgia 1999; 19: 402Google Scholar
  63. 63.
    Brandli P, Loffler B-M, Breu V, et al. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 1996; 64: 315–22PubMedGoogle Scholar
  64. 64.
    May A, Gijsman HJ, Wallnoefer A, et al. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996; 67: 375–8PubMedGoogle Scholar
  65. 65.
    Limmroth V, Lee WS, Cutrer FM, et al. GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. Br J Pharmacol 1996; 117: 99–104PubMedGoogle Scholar
  66. 66.
    Data J, Britch K, Westergaard N, et al. A double-blind study of ganaxolone in the acute treatment of migraine headaches with or without an aura in premenopausal females [abstract]. Headache 1998; 38: 380Google Scholar
  67. 67.
    Lee WS, Moussaoui SM, Moskowitz MA. Blockade by oral or parenteral RPR100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravsation in guinea-pig dura mater and conjunctiva. Br J Pharmacol 1994; 112: 920–4PubMedGoogle Scholar
  68. 68.
    Goldstein DJ, Wang O, Saper JR, et al. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997; 17: 785–90PubMedGoogle Scholar
  69. 69.
    Diener HC. Substance-P antagonist RPR100893-201 is not effective in human migraine attacks. In: Olesen J, Tfelt-Hansen P, editors. Proceedings of the VIth International Headache Seminar; 1995 Nov 17–19; Copenhagen. NewYork: Lippincott-Raven, 1996Google Scholar
  70. 70.
    Norman B, Panebianco D, Block GA. A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine [abstract]. Cephalalgia 1998; 18: 407Google Scholar
  71. 71.
    Connor HE, Bertin L, Gillies S, et al. The GR205171 Clinical Study Group. Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine [abstract]. Cephalalgia 1998; 18: 392Google Scholar
  72. 72.
    Goldstein DJ, Offen WW, Klein EG, et al. Lanepitant, an NK-1 antagonist, in migraine prophylaxis [abstract]. Cephalalgia 1999; 19: 377Google Scholar
  73. 73.
    Goadsby PJ, Hoskin KL, Knight YE. Substance Pblockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation. Neuroscience 1998; 86: 337–43PubMedGoogle Scholar
  74. 74.
    Hoskin KL, Goadsby PJ. CP122,288 has no effect on c-fos expression in the trigeminal nucleus caudalis after superior sagittal sinus stimulation [abstract]. Cephalalgia 1997; 17: 402Google Scholar
  75. 75.
    May A, Shepheard S, Wessing A, et al. Retinal plasma extravasation can be evoked by trigeminal stimulation in rat but does not occur during migraine attacks. Brain 1998; 121: 1231–7PubMedGoogle Scholar
  76. 76.
    Adham N, Kao H-T, Schechter LE, et al. Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A 1993; 90: 408–12PubMedGoogle Scholar
  77. 77.
    Branchek T, Archa JE. Recent advances in migraine therapy. In: Robertson DW, editor. Central nervous system disease. Annual reports in medicinal chemistry. San Diego: Academic Press, 1997: 1–10Google Scholar
  78. 78.
    Goldstein DJ, Roon KI, Offen WW, et al. Migraine treatment with selective 5-HT1F receptor agonist (SSOFRA) LY334370. Cephalalgia 1999; 19: 318Google Scholar
  79. 79.
    Goldstein DJ, Gossen D, Granier L. Clinical experience with LY334370, a selective serotonin 1F receptor agonist (SSOFRA): absence of cardiovascular effects. Cephalalgia 1999; 39: 366–7Google Scholar
  80. 80.
    Castro ME, Pascual J, Romon T, et al. Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacol 1997; 36: 535–42Google Scholar
  81. 81.
    Pascual J, Arco Cd, Romon T, et al. [3H]Sumatriptan binding sites in human brain: regional-dependent labelling of 5HT1D and 5HT1F receptors. Eur J Pharmacol 1996; 295: 271–4PubMedGoogle Scholar
  82. 82.
    Waeber C, Moskowitz MA. [3H]sumatriptan labels both 5-HT1D and 5HT-1F receptor bindings sites in the guinea pig brain: an autoradiographic study. Naunyn-Schmiedeberg’s Arch Pharmacol 1995; 352: 263–75Google Scholar
  83. 83.
    Goldstein J, Dahlof CGH, Diener H-C, et al. Alniditan in the acute treatment of migraine attacks: a subcutaneous dosefinding study. Cephalalgia 1996; 16: 497–502PubMedGoogle Scholar
  84. 84.
    Limmroth V, Wermelskirchen D, Tegtmeier F, et al. R91274 (alniditan) blocks neurogenic inflammation in the rat meninges more effectively than sumatriptan by activation of 5HT1D-receptors [abstract]. Neurology 1997; 48: 1137Google Scholar
  85. 85.
    Leysen JE, Gommeren W, Heylen L, et al. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1Dα, human 5-hydroxytryptamine1Dβ, and calf 5-hydroxytryptamine1D receptors investigated with [3H]-5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol 1996; 50: 1567–80PubMedGoogle Scholar
  86. 86.
    Waeber C, Cutrer FM, Yu X-J, et al. The selective 5HT1D receptor agonist U-109291 blocks dural plasma extravasation and c-fos expression in the trigeminal nucleus caudalis [abstract]. Cephalalgia 1997; 17: 401Google Scholar
  87. 87.
    Pregenzer JF, Alberts GL, Block JH, et al. Characterisation of ligand binding properties of the 5-HT1D receptors cloned from chimpanzee, gorilla and rhesus monkey in comparison with those from the human and guinea pig receptors. Neurosci Lett 1997; 235: 117–20PubMedGoogle Scholar
  88. 88.
    Pregenzer JF, Alberts GL, Im WB, et al. Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands). Br J Pharmacol 1999; 127: 468–72PubMedGoogle Scholar
  89. 89.
    Edvinsson L, Goadsby PJ. Neuropeptides in headache. Eur J Neurol 1998; 5: 329–41Google Scholar
  90. 90.
    Goadsby PJ, Sercombe R. Neurogenic regulation of cerebral blood flow: extrinsic neural control. In: Mraovitch S, Sercombe R, editors. Neurophysiological basis of cerebral blood flow control: an introduction. Paris: John Libbey and Co Ltd, 1996: 285–322Google Scholar
  91. 91.
    Goadsby PJ, Edvinsson L. Regulation of cerebral blood flow by the parasympathetic nervous system. In: Welch KMA, Caplan L, Reis DJ, et al., editors. Primer of cerebrovascular diseases. San Diego: Academic Press, 1997: 63–6Google Scholar
  92. 92.
    Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation ofman and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23: 193–6PubMedGoogle Scholar
  93. 93.
    Knight YE, Edvinsson L, Goadsby PJ. Blockade of release of CGRP after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288 [abstract]. Cephalalgia 1997; 17: 248Google Scholar
  94. 94.
    Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994; 34: 394–9PubMedGoogle Scholar
  95. 95.
    Knight YE, Connor HE, Edvinsson L, et al. Only 5HT 1B/1D agonist doses of 4991W93 inhibit CGRP release in the cat [abstract]. Cephalalgia 1999; 19: 401Google Scholar
  96. 96.
    Buzzi MG, Moskowitz MA, Shimizu T, et al. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacol 1991; 30: 1193–200Google Scholar
  97. 97.
    Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990; 16: 69–75PubMedGoogle Scholar
  98. 98.
    Tognetto M, Creminon C, Fusco BM, et al. CGRP release from guinea-pig trigeminal ganglia: effect of dihydroergotamine [abstract]. Cephalalgia 1999; 19: 403Google Scholar
  99. 99.
    Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995; 15: 384–90PubMedGoogle Scholar
  100. 100.
    Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 1994; 117: 427–34PubMedGoogle Scholar
  101. 101.
    Fanciullacci M, Alessandri M, Figini M, et al. Increases in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995; 60: 119–23PubMedGoogle Scholar
  102. 102.
    Lassen LH, Jacobsen VB, Petersen P, et al. Human calcitonin gene-related peptide (hCGRP)-induced headache in migraineurs [abstract]. Eur J Pharmacol 1998; 5 Suppl. 3: S63Google Scholar
  103. 103.
    Christiansen T, Bruun A, Knight YE, et al. Immunoreactivity of NOS, CGRP, PACAP, SP and MIP in the trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2: influence of stimulation of the superior sagittal sinus in the cat [abstract]. Cephalalgia 1999; 19: 396Google Scholar
  104. 104.
    Kaube H, Keay K, Hoskin KL, et al. Expression of c-fos-like immunoreactivity in the trigeminal nucleus caudalis and high cervical cord following stimulation of the sagittal sinus in the cat. Brain Res 1993; 629: 95–102PubMedGoogle Scholar
  105. 105.
    Kaube H, Hoskin KL, Goadsby PJ. Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat. Cephalalgia 1992; 12: 133–6PubMedGoogle Scholar
  106. 106.
    Hoskin KL, Kaube H, Goadsby PJ. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 1996; 119: 1419–28PubMedGoogle Scholar
  107. 107.
    Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the non-human primate brain macaca nemestrina: a c-fos immunocytochemical study. J Anat 1997; 190: 367–75PubMedGoogle Scholar
  108. 108.
    Hoskin KL, Zagami A, Goadsby PJ. Stimulation of the middle meningeal artery leads to bilateral Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat 1999; 194: 579–88PubMedGoogle Scholar
  109. 109.
    Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 1991; 114: 1001–11PubMedGoogle Scholar
  110. 110.
    Goadsby PJ, Knight YE, Hoskin KL. Processing of occipital pain in the caudal trigeminal nucleus: referred pain in primary headache [abstract]. Cephalalgia 1997; 17: 381Google Scholar
  111. 111.
    Goadsby PJ, Gundlach AL. Localization of [3H]-dihydroergotamine binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 1991; 29: 91–4PubMedGoogle Scholar
  112. 112.
    Mills A, Martin GR. Autoradiographic mapping of [3H]sumatriptan binding in cat brain stem and spinal cord. Eur J Pharmacol 1995; 280: 175–8PubMedGoogle Scholar
  113. 113.
    Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 1997; 17: 153–8PubMedGoogle Scholar
  114. 114.
    Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-Fos and electrophysiology study. Brain 1996; 119: 249–56PubMedGoogle Scholar
  115. 115.
    Goadsby PJ, Hoskin KL. Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in the cat. Pain 1999; 82: 15–22PubMedGoogle Scholar
  116. 116.
    Knight YE, Goadsby PJ. Naratriptan inhibits central trigeminal activity by a 5HT1B/1D receptor [abstract]. Cephalalgia 1997; 17: 403Google Scholar
  117. 117.
    Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 1997; 328: 37–40PubMedGoogle Scholar
  118. 118.
    Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)-1-D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain 1996; 67: 355–9PubMedGoogle Scholar
  119. 119.
    Kaube H, Hoskin KL, Goadsby PJ. Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Br J Pharmacol 1993; 109: 788–92PubMedGoogle Scholar
  120. 120.
    Shepheard SL, Williamson DJ, Williams J, et al. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in the dura mater and c-fos mRNA expression in the trigeminal nucleus caudalis of rats. Neuropharmacol 1995; 34: 255–61Google Scholar
  121. 121.
    Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994; 44: 1587–92PubMedGoogle Scholar
  122. 122.
    Goadsby PJ, Hoskin KL. Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5-HT1B/1D receptor: a central action in migraine? Ann Neurol 1998; 43: 711–8PubMedGoogle Scholar
  123. 123.
    Clitherow JW, Scopes DI, Skingle M, et al. Evolution of a novel series of [(N,N-dimethylamino) propyl]- and peperazinylbenzanilides as the first selective 5-HT1D antagonists. J Med Chem 1994; 37: 2253–7PubMedGoogle Scholar
  124. 124.
    Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 1997; 120: 2171–7PubMedGoogle Scholar
  125. 125.
    Proletti-Cecchini P, Afra J, Schoenen J. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1Dagonist zolmitriptan (311C90, Zomig). Cephalalgia 1997; 17: 849–54Google Scholar
  126. 126.
    Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of the auditory cortical evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic transmission? Neurology 1996; 46: 1404–9PubMedGoogle Scholar
  127. 127.
    Greene-Tallaksen SJ, Young AB, Penney JB, et al. Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat. Neurosci Lett 1993; 141: 79–83Google Scholar
  128. 128.
    Hill RG, Salt TE. An iontophoretic study of the responses of rat caudal trigeminal nucleus neurones to non-noxious mechanical sensory stimuli. J Physiol 1982; 327: 65–78PubMedGoogle Scholar
  129. 129.
    Salt TE, Hill RG. Differentiation of excitatory amino acid receptors in the rat caudal trigeminal nucleus: a microiontophoretic study. Neuropharmacol 1982; 21: 385–90Google Scholar
  130. 130.
    Mitsikostas DD, Sanchez del Rio M, Waeber C, et al. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 1998; 76: 239–48PubMedGoogle Scholar
  131. 131.
    Mitsikostas DD, Sanchez del Rio M, Waeber C, et al. Non-NMDA glutamate receptors modulate capsaicin induced cfos expression within trigeminal nucleus. Br J Pharmacol 1999; 127: 623–30PubMedGoogle Scholar
  132. 132.
    Storer RJ, Goadsby PJ. Trigeminovascular nociceptive transmission involves NMDA and non-NMDA glutamate receptors. Neuroscience 1999; 90: 1371–6PubMedGoogle Scholar
  133. 133.
    Classey JD, Knight YE, Goadsby PJ. MK-801 reduces Fos-like immunoreactivity in trigeminocervical complex of cat [abstract]. Cephalalgia 1999; 19: 394Google Scholar
  134. 134.
    Goadsby PJ, Classey JD. Blood flow responses in trigeminocervical complex involve glutamate [abstract]. Cephalalgia 1999; 19: 315Google Scholar
  135. 135.
    Storer RJ, Connor HE, Goadsby PJ. Microiontophoretic application of 4991W93 inhibits trigeminocervical neurons [abstract]. Cephalalgia 1999; 19: 314Google Scholar
  136. 136.
    Cumberbatch MJ, Hill RG, Hargreaves RJ. Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia 1998; 18: 659–64PubMedGoogle Scholar
  137. 137.
    Cumberbatch MJ, Hill RG, Hargreaves RJ. The effects of 5- HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats. Eur J Pharmacol 1998; 362: 43–6PubMedGoogle Scholar
  138. 138.
    Lance JW, Goadsby PJ. Mechanism and management of headache. 6th ed. London: Butterworth-Heinemann, 1998Google Scholar
  139. 139.
    Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944; 7: 359–90Google Scholar
  140. 140.
    Leao AAP. Further observations on the spreading depression of of activity in the cerebral cortex. J Neurophysiol 1947; 10: 409–14PubMedGoogle Scholar
  141. 141.
    Lauritzen M. Pathophysiology of the migraine aura: the spreading depression theory. Brain 1994; 117: 199–210PubMedGoogle Scholar
  142. 142.
    Cutrer FM, Sorensen AG, Weisskoff RM, et al. Perfusionweighted imaging defects during spontaneous migrainous aura. Ann Neurol 1998; 43: 25–31PubMedGoogle Scholar
  143. 143.
    Hansen AJ, Lauritzen M, Tfelft-Hansen P. Spreading cortical depression and antimigraine drugs. In: Amery WK, Nueten JMV, Wauquier A, editors. Pharmacological basis of migraine therapy. London: Pitman, 1982: 139–54Google Scholar
  144. 144.
    Kaube H, Goadsby PJ. Antimigraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur Neurol 1994; 34: 30–5PubMedGoogle Scholar
  145. 145.
    Chan WN, Evans JN, Hadley MS. Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agent. Bioorg Med Chem Lett 1999; 9: 285–90PubMedGoogle Scholar
  146. 146.
    Goadsby PJ, Kaube H, Hoskin K. Nitric oxide synthesis couples cerebral blood flow and metabolism. Brain Res 1992; 595: 167–70PubMedGoogle Scholar
  147. 147.
    Read SJ, Smith MI, Hunter AJ, et al. Enhanced nitric oxide release during cortical spreading depression following infusion of glyceryl trinitrate in the anaesthetized cat. Cephalalgia 1997; 17: 159–65PubMedGoogle Scholar
  148. 148.
    Read SJ, Smith MI, Hunter AJ, et al. The dynamics of nitric oxide release measured directly and in real time following repeated waves of cortical spreading depression in the anaesthetised cat. Neurosci Lett 1997; 232: 127–30PubMedGoogle Scholar
  149. 149.
    Read SJ, Smith MI, Hunter AJ, et al. SB-220453 inhibits cortical spreading depression (SD) associated NO release in the anaesthetised cat [abstract]. Cephalalgia 1999; 19: 403Google Scholar
  150. 150.
    Lassen LH, Ashina M, Christiansen I, et al. Nitric oxide synthesis inhibition in migraine. Lancet 1997; 349: 401–2PubMedGoogle Scholar
  151. 151.
    International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. Cephalalgia 1991; 11: 1–12Google Scholar
  152. 152.
    Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291–4PubMedGoogle Scholar
  153. 153.
    Visser WH, Vriend RHMD, Jaspers NMWH, et al. Sumatriptan in clinical practice: a 2 year review of 453 migraine patients. Neurology 1996; 47: 46–51PubMedGoogle Scholar
  154. 154.
    Visser WH, Jaspers NM, de Vriend RH, et al. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996; 16: 264–9PubMedGoogle Scholar
  155. 155.
    Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebocontrolled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997; 17: 647–51PubMedGoogle Scholar
  156. 156.
    Visser WH, Lines CR, Reines SA. Dose-finding studies of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1996; 16: 359–60Google Scholar
  157. 157.
    Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs sumatriptan in the acute treatment of migraine. Arch Neurol 1996; 53: 1132–7PubMedGoogle Scholar
  158. 158.
    Teall J, Tuchman M, Cutler N, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence: a placebo-controlled, outpatient study. Headache 1998; 38: 281–7PubMedGoogle Scholar
  159. 159.
    Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998; 38: 748–55PubMedGoogle Scholar
  160. 160.
    Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg vs sumatriptan 25mg and 50mg in migraine. Headache 1998; 38: 737–47PubMedGoogle Scholar
  161. 161.
    Dahlof C, Diener HC, Goadsby PJ, et al. Zolmitriptan, a 5HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol 1998; 5: 535–43PubMedGoogle Scholar
  162. 162.
    Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. Neurology 1997; 49: 1210–8PubMedGoogle Scholar
  163. 163.
    Solomon GD, Cady RK, Klapper JA, et al. Clinical efficacy and tolerability of 2.5mg zolmitriptan for the acute treatment of migraine. Neurology 1997; 49: 1219–25PubMedGoogle Scholar
  164. 164.
    Palmer KJ, Spencer CM. Zolmitriptan. CNS Drugs 1997; 7: 468–78Google Scholar
  165. 165.
    Goadsby PJ. Naratriptan in the treatment of acute migraine attacks. Prescriber 1997; 8: 89–97Google Scholar
  166. 166.
    Gobel H, Boswell D, Winter P, et al. A comparison of the efficacy, safety and tolerability of naratriptan and sumatriptan. Cephalalgia 1997; 17: 426Google Scholar
  167. 167.
    Milton KA, Allen MJ, Abel S, et al. The safety, tolerability, pharmacokinetics and pharmacodynamics of oral and intravenous eletriptan, a potent and selective “5HT1D-like” receptor partial agonist [abstract]. Cephalalgia 1997; 17: 44Google Scholar
  168. 168.
    Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology. In pressGoogle Scholar
  169. 169.
    Reches A, Eletriptan Steering Committee. Comparison of the efficacy, safety and tolerability of oral eletriptan and Cafergot® for the acute treatment of migraine [abstract]. Cephalalgia 1999; 19: 355Google Scholar
  170. 170.
    Ryan R, Keywood C. A preliminary study of VML251 (SB209509) a novel 5HT1B/1D agonist for the treatment of acute migraine [abstract]. Cephalalgia 1997; 17: 418Google Scholar
  171. 171.
    Rance D, Clear N, Dallman L, et al. Physicochemical comparison of eletriptan and other 5-HT1D-like agonists as a predictor of oral absorption potential [abstract]. Headache 1997; 37: 328Google Scholar
  172. 172.
    Winner P, Ricalde O, Force BL, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53: 180–4PubMedGoogle Scholar
  173. 173.
    Massiou H. Acomparison of sumatriptan nasal spray and intranasal dihydroergotamine (DHE) in the acute treatment of migraine [abstract]. Funct Neurol 1996; 11 (2/3): 151Google Scholar
  174. 174.
    Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996; 47: 361–5PubMedGoogle Scholar
  175. 175.
    The Swedish Medicines Agency. Sumatriptan versus cafergot suppositories. The Swedish Medicines Agency [online]. URL: http://www.mpa.se/sve/mono/imig.shtml [Accessed 1998]Google Scholar
  176. 176.
    Martin GR, Martin RS, Wood J. Long-acting 5-HT1D receptor agonist effects of dihydroergotamine. In: Olesen J, Moskowitz MA, editors. Experimental headache models. Philadelphia: Lippincott-Raven, 1995: 163–7Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Department of Clinical NeurologyInstitute of NeurologyLondonEngland

Personalised recommendations